Novel Agents in Breast Cancer and Monoclonal Antibodies
Howard A. “Skip†Burris, III, MD, president, Clinical Operations, chief medical officer and executive director, Drug Development Program, Sarah Cannon, discusses the novel agents in breast cancer and monoclonal antibodies.
Burris mentions the many new classes of therapies discussed for breast cancer, as well as the focus on drugs that will target receptors on the cancer cells and potentially stimulate the immune system.
He also explains the positive results discovered from the treatment of margetuximab in patients.
Howard A. “Skip” Burris, III, MD, president, Clinical Operations, chief medical officer and executive director, Drug Development Program, Sarah Cannon, discusses the novel agents in breast cancer and monoclonal antibodies.
Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer
May 16th 2024During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
